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CD8 T cellsMicroparticulate b-glucan (MG) conjugated to vaccine antigen has been shown to serve as an effective
adjuvant in vivo. To further study antigen presentation by MG:vaccine conjugates, bone marrow-
derived dendritic cells (BMDC) were treated with MG conjugated to ovalbumin (OVA), then interacted
with splenocytes from DO11.10 transgenic mice expressing an OVA peptide-specific T cell receptor.
BMDC treated with MG:OVA induced significantly higher numbers of activated (CD25+CD69+) OVA-
specific CD4+ T cells than BMDC treated with OVA alone. BMDC treated with MG:OVA upregulated
CD86 and CD40 expression as well as MG alone, indicating that conjugation of OVA does not alter the
immunostimulatory capacity of MG. Activation of CD8+ OVA-specific OT-1 cells showed that MG:OVA
is also capable of enhancing cross-presentation by BMDC to CD8+ cytotoxic T cells. These results show
that MG acts as an adjuvant to enhance antigen presentation by dendritic cells to naïve, antigen-
specific CD4 and CD8 T cells.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fungal b-glucan is a pathogen-associated molecular pattern
(PAMP) that binds to a variety of pathogen recognition receptors,
most notably dectin-1 on macrophages and dendritic cells [1–5].
It has been studied extensively for its immunostimulatory proper-
ties [4,6–8]. The interaction between b-glucan and its receptors
serves as an activating signal that promotes anti-fungal immunity
[9–11], but fungal b-glucan also has a long history of use as an
adjuvant to promote immune responses to tumors and other
microorganisms [12–16]. We prepared a microparticulate form of
b-glucan from Saccharomyces cerevisiae [17] and demonstrated that
it upregulates the cell surface expression of antigen-presenting
MHC molecules and B7 family co-stimulatory molecules on macro-
phages [18] and induces the production of proinflammatory
cytokines [19]. Microparticulate b-glucan (MG) was shown to exhi-
bit adjuvant activity when conjugated to a test vaccine antigen and
administered to mice via intradermal injection or oral immuniza-
tion [20]. Recent studies have confirmed that b-glucan particles
can be used to deliver vaccine antigen for oral immunization
[21–23]. In the present study we endeavored to probe the mecha-
nisms involved in the adjuvant effect of MG. In particular, wewanted to demonstrate that an antigen conjugated to MG would
be processed into peptides in bone marrow-derived dendritic cells
(BMDC) and presented to CD4 T cells in the context of MHC Class II
molecules, and also cross-presented to CD8 T cells by MHC Class I
molecules.
For these studies we employed DO11.10 transgenic mice engi-
neered to express a single T cell receptor with specificity for an
ovalbumin peptide (OVA323–339) in the context of MHC class II
[24,25]. The cell surface upregulation of the T cell activation mark-
ers CD25 (IL-2 receptor a chain) [26,27] and CD69 [28] was used to
assess successful antigen presentation. We found that MG:OVA-
treated BMDC, but not BMDC cells treated with OVA alone, acti-
vated naive CD4+ OVA-specific T cells. Although phagocytized
MG:OVA reside in vesicles, there is evidence that vesicular anti-
gens normally processed and presented by MHC class II molecules
can be cross-presented on MHC class I molecules, and that these
cells can activate CD8+ T cells [29–32]. To determine whether
MG:OVA-treated BMDC processed and presented OVA peptides in
the context of MHC class I molecules, we tested CD8+ T cells from
OT-1 transgenic mice that express T cell receptors specific for
OVA257–264 peptide in the context of MHC class I [33]. We found
that MG:OVA-treated BMDC activated naïve OVA-specific CD8+ T
cells, indicating that vaccine antigens attached to MG can activate
not only CD4+ T cells, but also CD8+ T cells. MG:OVA conjugates
facilitated the upregulation of CD86 and CD40 co-stimulatory
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an adjuvant that can enhance both CD4-mediated inflammatory
and CD8-mediated cytotoxic T cell responses.
2. Materials and methods
2.1. Reagents
Microparticulate b-glucan was prepared as described [17]. An
endotoxin-specific Limulus amebocyte lysate assay (PyroTurb ES,
Associates of Cape Cod Inc., Falmouth, MA) was used to verify that
all MG preparations used in cell culture were free of endotoxin.
Ovalbumin from chicken egg white (OVA), lipopolysaccharide
(LPS) from Escherichia coli strain O111:B4, and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC) were purchased from
Sigma (St. Louis, MO). Murine recombinant IFN-c was obtained
from Chemicon International (Temecula, CA), and murine recombi-
nant IL-2 was obtained from Endogen Inc. (Woburn, MA). Murine
recombinant GM-CSF was purchased from BioSource International
(Camarillo, CA).
2.2. Mice
Female BALB/c wild-type mice 6–8 wks of age were obtained
from Charles River Laboratories through the National Institutes of
Health (Bethesda, MD). Female 6–8 wk old DO11.10 (BALB/c back-
ground) mice with transgenic T cell receptors reactive with
OVA323–339, and female 6–8 wk old OT-1 (C57BL/6 background)
mice with T cell receptors specific for OVA257–264, were obtained
from the Jackson Laboratory. All mice were housed in microisola-
tors in a temperature-controlled facility with a 12-h photoperiod
and given food and water ad libitum. Mice were euthanized prior
to primary cell harvest by isofluorane inhalation. All experiments
were done under an approved protocol from the University of
Nevada, Reno Institutional Animal Care and Use Committee.
2.3. Preparation of MG:OVA conjugates
MG:OVA conjugates were prepared by the carbodiimide
method previously described [20]. Briefly, 40 mg of EDAC was
added to 10 mg of MG at 5 mg/ml in sterile, pyrogen-free dH2O.
The pH of the mixture was adjusted to 4.5 using 0.1 M NaOH.
The mixture was incubated on a rocker for 16 h at room tempera-
ture (RT), centrifuged at 800g for 10 min at room temperature to
pellet the MG, and washed 3 with 5 ml sterile pyro-free dH2O to
remove unbound EDAC. After the final wash, 5 ml of a 2 mg/mlTable 1
List of antibodies.
Reagent Supplier Cat. no.
Anti-mouse CD16/32 (Fc Block) eBioscience 14-0161
Rat IgG Jackson Immuno. 012-000
FITC-anti-mouse CD8a (Ly-2) eBioscience 11-0081
PE-Cy5-anti-mouse CD3e eBioscience 15-0031
PE-Cy7-anti-mouse CD4 eBioscience 25-0041
PE-anti-mouse CD25 eBioscience 12-0251
PE-Rat-IgG1 k (Ctrl) eBioscience 12-4301
PE-anti-mouse CD69 eBioscience 12-0691
PE-Hamster-IgG (Ctrl) eBioscience 12-491
FITC-anti-mouse Ly-6C PharMingen 553104
PE-Cy5-anti-mouse CD11c eBioscience 15-0114
PE-anti-mouse CD40 eBioscience 12-0401
PE-anti-mouse CD86 (B7.2) eBioscience 12-0862
PE-Rat-IgG2a k (Ctrl) eBioscience 12-432
PE-anti-human Granzyme B Caltag MHGB0
PE-anti-mouse IgG1 k (Ctrl) eBioscience 12-471solution of OVA in pyro-free dH2O was added to the EDAC-
conjugated MG and the pH was adjusted to 4.5 as above. This
mixture was incubated at RT for 6 h with rocking. Following
incubation, the MG conjugates were washed 3 as before to
remove unbound OVA and resuspended in sterile pyro-free
phosphate-buffered saline (PBS). Concentration of particles in solu-
tion was determined by spectrophotometry; percent transmittance
at 600 nm was used to back-calculate concentration from a
standard curve prepared using known concentrations of MG.
A competitive inhibition ELISA-based assay was used to obtain
rough estimates of conjugated OVA per mg of MG. For MG:OVA
preparations used in these experiments, conjugates contained
roughly 10 lg OVA per mg MG. In previous studies, the concentra-
tions of antigen bound to MG were determined using radiolabeled
protein [20]. These studies indicated that estimates obtained from
the competitive inhibition ELISA may be somewhat low (unpub-
lished data), but for our purposes in the present study, an estimate
of relative amounts of OVA on MG was sufficient.
2.4. Primary cell culture
BMDC were prepared according to the method of Lutz et al.
[34]. Briefly, the femurs and tibia of female, 6–8 wk old BALB/c
or OT-1 mice were removed and the surrounding muscle tissue
was cut away and rubbed off with Kimwipe tissues (Kimberly-
Clark, Roswell, GA). Intact bones were placed in 70% ethanol for
2–3 min, then rinsed in sterile pyro-free PBS. Epiphyses were
removed with sterile scissors and marrow was flushed with
pyro-free PBS using a 1/2 in, 27G needle. The suspension was
pipetted several times to disperse clusters of cells, and cells were
centrifuged at 300g for 6 min. After one wash in 10 ml pyro-
free PBS, viable leukocytes were counted by trypan blue exclusion.
Cells were seeded at day 0 in bacteriological Petri dishes (Fisher-
brand, Fisher Scientific, Pittsburgh, PA) at 2  106 leukocytes per
100 mm dish in 10 ml of complete RPMI-1640 supplemented with
10% FBS, 2 mM L-glutamine, 100 U penicillin, 100 lg streptomycin,
50 mM sodium pyruvate (Cambrex), 50 lM 2-mercaptoethanol
(Gibco, Invitrogen, Carlsbad, CA), and 20 ng/ml GM-CSF. Cells
were incubated in a humidified incubator at 37 C, 5% CO2. On
day 3 of culture another 10 ml of medium containing 20 ng/ml
GM-CSF were added to the cultures. On days 6 and 8, 10 ml of cul-
ture supernatant was removed, centrifuged at 300g for 6 min,
and cells were resuspended in 10 ml of fresh medium containing
20 ng/ml GM-CSF.
For experiments in which BMDC were utilized as antigen-
presenting cells for responder splenocyte populations,Lot Isotype Clone
-85 E009307 R IgG2b k 93
-003 63278 Rat IgG n/a
-85 E05703 R IgG2a k 53–6.7
-82 E011842 Ar H IgG 145-2C11
E008185 R IgG2b k GK1.5
-81 E006149 R IgG1 L PC61.5
-82 E013429 R IgG1 k eBRG1 (?)
-81 E010716 H IgG H1.2F3
5 E004349 H IgG n/a
5213 R IgM K AL-21
-81 E010588 H-IgG N418
-81 E011600 R IgG2aK 1C10
-81 E011657 R IgG2a K GL1
1-81 E011290 R IgG2a k eBR2a (?)
4 5010605 M IgG1 GB12
9 E003397 M IgG1 k MOPC-21/P3
Fig. 1. Gating strategy and representative dot plots of DO11.10 splenocytes incubated for 24 h (a) or 96 h (b) with untreated BMDC or BMDC treated with 4.0 lg MG
conjugated with OVA. Cells were first gated on CD3+ expression followed by a gate on CD4+ expression. Cells gated on CD4 expression are displayed on side scatter vs. CD25
or isotype control staining for each treatment. The percent of total cells in each gated population is portrayed on the plot.
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Fig. 1 (continued)
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trifuged, resuspended in fresh medium containing 5 ng/ml GM-CSF
and plated at 4  105 cells per well in 6-well TC plates. Cells wereincubated for 4–6 h before stimulation with OVA antigen plus or
minus MG. 16 h following treatment, spleens were harvested
from DO11.10 or OT-1 mice, processed into single-cell suspensions,
Fig. 2. Representative dot plots of DO11.10 splenocytes incubated for 24 h (a) or 96 h (b) with 4.0 lg MG conjugated with OVA. Cells were first gated on CD3+ expression
followed by a gate on CD4+ expression as shown in Fig. 1. Cells gated on CD4 expression are displayed on side scatter vs. CD69 or isotype control staining for each treatment.
The percent of total cells in each gated population is portrayed on the plot.
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Fig. 3. BMDC treated with MG:OVA activate naive DO11.10 CD4 T cells. BMDC were
treated with 1.0 lg/ml OVA, 4.0 lg MG conjugated with OVA, or 4.0 lg MG for 16 h,
followed by addition of DO11.10 splenocytes for 24 h (a) or 96 h (b). Results
displayed are percent of total CD3+CD4+ cells positive for CD25 or CD69 expression
(refer to Figs. 1 and 2 for gating strategy). The data are compiled from three
independent experiments (means ± one standard deviation), and both CD25 and
CD69 in the MG:OVA group were significantly different from the other treatment
groups (p < 0.001).
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treated BMDC at 3.5  106 leukocytes per well. Mixed cell cultures
were incubated for 24, 48, or 96 h before harvesting for flow
cytometry. In OT-1 cultures, cultures received 10 ng/ml rIL-2 at
the start of the culture period.2.5. Antibodies and flow cytometry
The antibodies used in these studies are listed in Table 1. Anti-
bodies were diluted in BioSure sheath solution (PBS supplemented
with 1% FBS and 0.1% sodium azide and filtered through a 0.2 lm
filter). Non-adherent splenocytes were harvested by gentle pipet-
ting and BMDC were harvested from plates by gentle scraping with
cell lifters (Fisherbrand, Fisher Scientific). Cells were centrifuged
at 300g for 6 min at 4 C, then washed once in 3 ml ice-cold stain-
ing buffer containing Hanks’ balanced salt solution (without phe-
nol red, sodium bicarbonate, calcium, or magnesium) (Cellgro,
Mediatech Inc., Herndon, VA), 1% FBS (Hyclone) and 0.1% sodium
azide. To reduce non-specific binding of immunoglobulins, cells
were treated for 15–30 min on ice with a mixture of Fc block
(anti-CD16/32) and rat IgG. Following incubation with Fc block,
50 ll cell aliquots were added to tubes containing diluted labeled
antibodies (10 ll of each antibody) and incubated for 40 min at
4 C in the dark. Cells were washed once in 2 ml of ice-cold staining
buffer and resuspended in 0.5 ml fresh staining buffer. An intracel-
lular staining protocol using IntraPrep Reagents (Beckman-Coulter)
was followed for OT-1 cells incubated with anti-Granzyme B [35].Cells were first labeled with appropriate anti-surface antibodies for
15 min at room temperature, then fixed with IntraPrep Reagent #1
for 15 min. Four ml of PBS was added and cells were washed by
centrifugation. IntraPrep Reagent #2 was added to permeabilize
the cells for 5 min at room temperature, then PE-anti-Granzyme
B or PE-anti-MIgG1 isotype control antibody was added to tubes
and incubated for 15 min. The wash step was repeated and cells
were resuspended in 0.5 ml PBS containing 0.5% formaldehyde.
Cells were analyzed using a four-color Beckman Coulter EPICS
XL-MCL Flow Cytometer (Beckman Coulter Inc., Miami, FL) modi-
fied to detect fluorescence from FITC, PE, PC5 and PC7. This non-
standard instrument configuration has been described in detail
[36]. Listmode data files were analyzed using FlowJo software
(Tree Star Inc., Ashland, OR).
2.6. Data analysis
In these experiments the expression of cell surface and intracel-
lular markers associated with activated CD4 (CD25 and CD69) and
CD8 (CD25 and Granzyme B) T cells was measured by flow cytom-
etry. Upregulation of these markers on the T cells after co-culture
with BMDC treated in various ways was assessed by staining with
fluorochrome-tagged antibodies and analysis by flow cytometry.
Gates were set to capture activated T cells identified by their
increased fluorescence intensity when compared with isotype con-
trols. Activated T cells were analyzed at 24 and 96 h after stimula-
tion with BMDC, and at both time points the population of
activated cells also reflected proliferation of these cells. For ease
of presentation, rather than using cell counts, the percentage of
total cells in the activation gate was used as the metric. However,
statistical analyses were done by ANOVA and Students’ t Test using
the actual cell counts.
3. Results
3.1. Gating strategy for analyzing the activation of OVA-specific CD4+
T cells by BMDC treated with MG:OVA conjugates
Whole OVA protein was conjugated to MG using a carbodiimide
reagent as described in Section 2. Unfractionated splenocytes from
DO11.10 mice were cultured with BMDC that had been stimulated
with MG:OVA vaccine conjugates or OVA alone for the previous
16 h. After incubation for 24 h, non-adherent cells were harvested
from the cultures and stained with fluorescent markers for flow
cytometry. Activation was verified by presence of activation mark-
ers CD25 and CD69 [26–28], and results are displayed as percent of
CD4+ T cells positive for these markers. These cell surface markers
were examined on the same sets of cells but not simultaneously (in
the same tube).
Fig. 1 shows representative dot plots that demonstrate the gat-
ing strategies for assessing the activation of OVA-specific CD4+ T
cells by untreated BMDC and BMDC treated with MG:OVA conju-
gates. T cells were analyzed by gating first on CD3+ cells, followed
by a CD4+ gate to exclude CD8+ T cells. Representative dot plots of
24 h or 96 h splenocytes incubated with untreated BMDC, or BMDC
treated with MG:OVA, are shown in Fig. 1a and b respectively. The
cells were stained with anti-CD25 or isotype control antibody.
Note the much larger percentage of CD25 positive cells after the
96 h incubation. Fig. 2 shows representative dot plots of staining
with anti-CD69 or isotype control antibody at 24 (a) and 96 h (b)
using the same CD3+CD4+ gates demonstrated in Fig. 1. By 96 h,
the majority of cells in the MG:OVA-treated culture were activated
CD3+CD4+ T cells, indicating that significant expansion of the acti-
vated population had occurred. Very little proliferation was evi-
dent in OVA-treated cultures, and this did not differ from
untreated control cells.
Fig. 4. BMDC upregulate CD86 and CD40 in response to MG:OVA. BMDC treated with OVA 1 lg/ml, MG 4.0 lg, or 4.0 lg MG conjugated with OVA were harvested at the same
time point as parallel cultures that had been incubated with splenocytes for 24 h. CD86 (a) and CD40 (b) expression is shown vs. CD11c staining to characterize responding
BMDC populations. Representative isotype control plots are displayed, and median fluorescence intensity values of the gated cells are portrayed on the plots. The data are
representative of three independent experiments.
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Fig. 5. MG:OVA induces CD8+ antigen-specific naïve T cell activation. BMDC were treated with 4.0 lg MG conjugated with OVA or soluble OVA (1.0 lg/ml) for 16 h followed
by addition of OT-1 splenocytes. Cells were harvested after 96 h. A gating strategy similar to DO11.10 experiments was used; cells were first gated on CD3+ T cells, then CD8+
cells were displayed on side scatter vs. CD25 or isotype control (a) and Granzyme B or isotype control (b). The percent of total cells in each gated population is portrayed on
the plot. Data are representative of two independent experiments.
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specific CD4+ T cells
Fig. 3a demonstrates that by 24 h there were more than three
times the number of activated T cells (CD25+CD69+) in splenocyte
populations from BMDC cultures treated with MG:OVA. BMDC
treated with OVA alone were not able to stimulate activation ofnaïve CD4+ T cells. OVA alone treatment was similar to the no
treatment at all, and MG given alone (without OVA) resulted in
no increase in T cell activation. By 96 h, T cell activation in MG:
OVA stimulated cells were increased more than 8-fold (Fig. 3b).
Activation induced by OVA alone at this time point was not differ-
ent from the untreated controls. These findings indicate that MG:
OVA BMDC can activate naïve CD4 T cells.
Fig. 5 (continued)
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BMDC
To correlate the activation of T cells with the effect of MG on
BMDC maturation, parallel cultures of BMDC that received treat-
ments, but not splenocytes, were harvested at 24 h and analyzed
for expression of the co-stimulatory molecules CD86 and CD40.
Gates were chosen to identify the CD11c+CD86+ cells or CD11c
+CD40+ cells, and the median fluorescence intensity (MFI) wascalculated for these cell populations. Compared to untreated BMDC
or BMDC treated with OVA alone, BMDC treated withMG:OVA dou-
bled CD86 expression (Fig. 4a), and CD40 expression was increased
50% (Fig. 4b). The upregulation of CD86 and CD40 was comparable
to that observed with MG alone, indicating that the OVA conjuga-
tion procedure did not degrade the ability of MG to upregulate
co-stimulatory molecule expression. These data indicate that the
sameMG:OVA preparation that can activate naïve CD4+ T cells also
induces costimulatory molecule expression on BMDC.
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CD8+ T cells
We questioned whether BMDC treated with MG:OVA conju-
gates were capable of cross-presenting antigen to naïve CD8+
OVA-specific T cells. To answer this, BMDC from OT-1 mice were
treated with MG:OVA or OVA alone followed by addition of OT-1
splenocytes as described in Section 2. Mixed cultures were incu-
bated for 96 h in the presence of IL-2, and then harvested for flow
cytometry. Cells were first gated on CD8, then plotted as side scat-
ter vs. CD25 or Granzyme B [35]. The percentage of total cells in
these gates was then calculated. These experiments showed that
MG:OVA was able to activate CD8+ OVA-specific T cells. There
were three times more CD25+ T cells present in MG:OVA treated
cultures than in cultures treated with soluble OVA or untreated
cultures (Fig. 5a). Similarly, MG:OVA treated cultures had more
than four times the number of Granzyme B+ cells (Fig. 5b). These
data strongly suggest that antigen attached to phagocytized MG
is processed and presented on MHC class I molecules in amounts
sufficient to activate naïve CD8+ T cells.4. Discussion
The early studies of b-glucan as a vaccine adjuvant involved the
introduction of b-glucan and vaccine antigen separately [12–16]. In
more recent studies, yeast ghosts derived from S. cerevisiae loaded
with antigen provided an effective immunization [7,21]. Although
not chemically attached to the b-glucan bearing particle, this pro-
cedure still associated the antigen with the particle, thus allowing
the delivery of antigen into the antigen-presenting cell by
phagocytosis.
We have previously shown that MG has immunostimulatory
effects on macrophages that result in upregulation of MHC and
costimulatory molecules, and we have also demonstrated that
mice immunized with MG:vaccine conjugates mount enhanced
antibody responses to vaccine antigen [18,20]. In the present study
we designed experiments to test the ability of MG:OVA conjugates
(versus soluble OVA protein) to be taken up, processed, and pre-
sented in MHC class I and class II molecules in a manner capable
of activating naïve antigen-specific T cells. DO11.10 T cells recog-
nize only a single peptide epitope of OVA presented in the context
of MHC class II [24,25]. We treated BMDC with whole soluble OVA
protein or whole OVA conjugated to MG to determine whether this
protein could be processed into peptide fragments and presented
to naïve T cells in a manner sufficient to obtain activation. The cell
surface upregulation of the T cell activation markers CD25 [26,27]
and CD69 [28] was used to assess successful antigen presentation.
DO11.10 cells showed little to no response to BMDC treated with
soluble OVA. This may have resulted from a lack of sufficient co-
stimulation, as BMDC did not appreciably upregulate CD86 or
CD40 in response to soluble OVA treatment. In addition, we
demonstrated that conjugation of OVA to MG did not alter its abil-
ity to upregulate CD86 or CD40. Thus, the present studies demon-
strated that BMDC treated with MG:vaccine conjugates enhance
antigen-specific T cell responses in vitro.
We showed that MG:OVA-stimulated BMDC enhanced activa-
tion of OVA-specific CD4+ T cells (DO11.10 T cells), but we were
also interested in determining whether MG:OVA could induce
BMDC to directly stimulate CD8+ cytotoxic T cells. A number of
studies have now shown that exogenous antigens can also enter
the MHC class I pathway; this is termed ‘‘cross-presentation”
[29–32]. We hypothesized that OVA chemically conjugated to
MG via a carbodiimide linkage would facilitate the cross-
presentation to CD8 cells. Howland et al. [37] had demonstrated
that a cancer vaccine antigen chemically conjugated to whole yeastor yeast hulls was able to cross-prime naïve CD8 T cells in vitro.
More recently, Huang et al. [38] demonstrated that OVA com-
plexed inside hollow yeast glucan shells was processed by BMDC
and activated both CD4 and CD8 T cells as measured by tritiated
thymidine incorporation. To see if a similar cross-presentation of
OVA peptides to CD8 T cells was possible with MG:OVA, we used
splenocytes from OT-1 mice where most of the CD8 T cells have
a receptor specific for the OVA257–264 peptide [33]. We found that
BMDC treated with MG:OVA activated naïve CD8+ cells not only
in terms of increased CD25 expression, but also in increased
expression of a functional cytotoxic molecule, Granzyme B [35].
Although Howland et al. [37] used a site-specific conjugation
method and enzymatically sensitive linkers to facilitate cross-
presentation, our simple carbodiimide linkage allowed the pro-
cessing of sufficient peptide to activate CD8 T cells.
These studies have demonstrated that MG:vaccine conjugates
taken up by BMDC are capable of activating naïve CD4+ and CD8
+ antigen-specific T cells in vitro. These findings substantiate the
hypothesis that MG can serve as a vaccine adjuvant and provide
insight into its mode of action. Further studies should seek to fully
characterize immune responses to MG and MG:vaccine conjugates
in vivo in order to determine if MG can be utilized safely and effec-
tively in clinical applications.
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